WEE1 and cancer: In the past decade, WEE1 inhibition has been developed as an anti-cancer therapy that targets a cell cycle checkpoint activated in response to DNA damage, and therefore, has been tested as both a single agent therapy and in combination with DNA damaging agents such as gemcitabine, carboplatin and cisplatin7, 8, 9, 10, 11, 12, 13, 14, 15.